Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,558,769
  • Shares Outstanding, K 73,487
  • Annual Sales, $ 57,990 K
  • Annual Income, $ -134,230 K
  • 60-Month Beta 2.14
  • Price/Sales 194.95
  • Price/Cash Flow N/A
  • Price/Book 26.25
Trade NTLA with:

Options Overview

Details
  • Implied Volatility 66.48%
  • Historical Volatility 55.75%
  • IV Percentile 2%
  • IV Rank 2.75%
  • IV High 142.93% on 12/21/20
  • IV Low 64.31% on 09/15/21
  • Put/Call Vol Ratio 0.63
  • Today's Volume 2,669
  • Volume Avg (30-Day) 1,214
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 12,004
  • Open Int (30-Day) 10,355

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.84
  • Number of Estimates 8
  • High Estimate -0.63
  • Low Estimate -1.20
  • Prior Year -0.47
  • Growth Rate Est. (year over year) -78.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
140.45 +11.99%
on 08/20/21
180.59 -12.90%
on 09/07/21
+3.84 (+2.50%)
since 08/17/21
3-Month
74.65 +110.70%
on 06/18/21
202.73 -22.41%
on 06/30/21
+80.79 (+105.61%)
since 06/17/21
52-Week
18.81 +736.20%
on 10/02/20
202.73 -22.41%
on 06/30/21
+134.84 (+600.62%)
since 09/17/20

Most Recent Stories

More News
New Strong Sell Stocks for August 24th

BGS, FTHM, NTLA, LEVL, and ELOX have been added to the Zacks Rank #5 (Strong Sell) List on August 24, 2021

BGS : 30.00 (+1.87%)
NTLA : 157.29 (+2.24%)
ELOX : 1.8700 (+6.86%)
LEVL : 28.24 (+0.43%)
FTHM : 29.72 (+4.17%)
Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why

Editas' (EDIT) lead candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating hematologic diseases.

BEAM : 102.91 (+0.82%)
EDIT : 63.20 (+3.61%)
NTLA : 157.29 (+2.24%)
CRSP : 124.52 (+6.05%)
How Are Genomics ETFs Responding to Q2 Earnings?

Let's take a look at some big genomics earnings releases to see if these will impact ETFs exposed to the space.

BEAM : 102.91 (+0.82%)
EDIT : 63.20 (+3.61%)
PBE : 77.70 (+1.38%)
NTLA : 157.29 (+2.24%)
CRSP : 124.52 (+6.05%)
ARKG : 83.93 (+3.01%)
GNOM : 24.22 (+3.15%)
IDNA : 55.20 (+1.56%)
S&P, NASDAQ Set New Highs While Waiting for Jobs Report

S&P, NASDAQ Set New Highs While Waiting for Jobs Report

RXT : 14.85 (-1.79%)
MTRN : 71.14 (+1.35%)
CRSP : 124.52 (+6.05%)
BEAM : 102.91 (+0.82%)
APLS : 34.21 (+0.62%)
NTLA : 157.29 (+2.24%)
ONCT : 4.24 (+1.44%)
EDIT : 63.20 (+3.61%)
PACB : 29.44 (+6.71%)
CCRN : 20.82 (+1.02%)
ALTO : 4.82 (-1.83%)
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -65.57% and -45.54%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?...

NTLA : 157.29 (+2.24%)
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?

Investor focus is likely to be on updates on pipeline candidates, especially NTLA-2001, when Intellia (NTLA) reports second-quarter earnings.

REGN : 651.88 (-0.20%)
MRNA : 430.05 (-2.41%)
PRTA : 77.07 (+3.05%)
NTLA : 157.29 (+2.24%)
Intellia Therapeutics, Inc. (NTLA) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Intellia Therapeutics, Inc. (NTLA) closed at $132.37, marking a -1.22% move from the previous day.

NTLA : 157.29 (+2.24%)
A Comprehensive Guide to Genomic ETFs

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

BEAM : 102.91 (+0.82%)
EDIT : 63.20 (+3.61%)
PBE : 77.70 (+1.38%)
NTLA : 157.29 (+2.24%)
CRSP : 124.52 (+6.05%)
ARKG : 83.93 (+3.01%)
GNOM : 24.22 (+3.15%)
IDNA : 55.20 (+1.56%)
3 Biotech Stocks Poised to Gain in the Second Half of 2021

Here we present three biotech companies, which outperformed the sector in the year so far and are likely to witness a winning run in the near term.

REGN : 651.88 (-0.20%)
BIIB : 300.19 (+0.17%)
AMGN : 219.38 (+0.93%)
MRNA : 430.05 (-2.41%)
RGEN : 306.90 (+2.34%)
NTLA : 157.29 (+2.24%)
BNTX : 359.18 (-3.61%)
Thinking about trading options or stock in Nio, Intellia Therapeutics, Advanced Micro Devices, Exxon Mobil, or Apple?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, NTLA, AMD, XOM, and AAPL.

AMD : 103.88 (-2.20%)
AAPL : 146.06 (-1.83%)
NTLA : 157.29 (+2.24%)
NIO : 37.51 (+1.13%)
XOM : 55.16 (-1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with...

See More

Key Turning Points

3rd Resistance Point 175.25
2nd Resistance Point 167.04
1st Resistance Point 162.17
Last Price 157.29
1st Support Level 149.09
2nd Support Level 140.88
3rd Support Level 136.01

See More

52-Week High 202.73
Last Price 157.29
Fibonacci 61.8% 132.47
Fibonacci 50% 110.77
Fibonacci 38.2% 89.07
52-Week Low 18.81

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar